Shop Planters Vision: Stroke: Treatment considerations and market entry

This report presents the results of a worldwide survey of current prescribing practices and treatments for ischemic stroke, hemorrhagic stroke and transient ischemic attack (TIA). These results were in connection to the participation of more than 230 hospitals around the world, the details of her treatment was made available practices.This carried out as part of a competitor and an overview of inclusion in the study area of ​​the market in the race.

In 2008, told the World Stroke Congress that 20 million of disease events occur worldwide each year, accounts for 5.7 million deaths. The Stroke is the second leading cause of death worldwide and a leading cause of disability. The incidence of stroke is expected to increase 30% over the next ten years (the 6th World Stroke Congress, Vienna, Austria from 24 to 27 September 2008).

In an area where therapies are often inadequate, doctors are looking to expand in order to improve their understanding and use of treatments available <-! next page -> outcomes. Knowledge in these areas is also important to drug developers a better understanding of prescribing practices and treatment needs and limitations from the perspective of the physician to develop through their own efforts to seek more effective therapies. Carried out to answer an interest in these areas Biopharm reports a global survey of current therapies and prescription drugs for stroke. The investigation included the participation of over 230 clinical centers in 41 countries.

Overview:

comprehensive quantitative data on treatments and practices for the prescription drugs ischemic stroke, hemorrhagic stroke and transient ischemic attack (TIA) Contributed by more than 230 clinics in 41 countries. Over 98% of survey participants are doctors who work in areas of stroke treatment. Specialist in diseases of which 65% are <-! Next Page -> Process. Large participating countries were the United States, Italy, India, Canada, Japan, Germany, Spain, Belgium and China.

About 60% of the participating clinical centers in this study were specialized hospital units, clinics or private practice specializing in diseases of diseases.

Detailed information about the classes

drugs in the treatment of patients with ischemic stroke, hemorrhagic stroke and transient ischemic attack (TIA) is used, together with the population profiles prescription drug.

Quantitative data on the specific prescription antiplatelet agents, anticoagulants, thrombolytics and other drugs in the treatment of ischemic stroke, hemorrhagic stroke and transient ischemic attack (TIA) is used.

The proportion of patients prescribed with ischemic stroke therapy with antiplatelet therapy of aspirin (eg Aspro ®), dipyridamole (eg, Persantine ®), clopidogrel (Plavix ® for example), the aspirin / dipyridamole (eg Asasantin ®), ticlopidine ( Ticlid ® for example) and others () indicated.

The proportion of

<-! next page -> prescribed to patients with ischemic stroke coagulant warfarin (such as Coumadin ®), heparin (eg Hepalean ®), dicoumarol (dicoumarol for example), antithrombin III (eg Thrombate ® III), argatroban (eg Novastan ®), bivalirudin (Angiomax ®, for example), sandoparin (eg Certoparin ®), enoxaparin, nadroparin (Lovenox ® for example), biscoumacetate acetate (ex Tromexan ®), (Fraxiparine ®, for example) or other (specified)

The proportion of patients with ischemic stroke, the drug prescribed thrombolytic plasminogen activator (alteplase, for example ®) or others () indicated.

The proportion of hemorrhagic stroke patients prescribed clotting factor (eg vitamin K), the clotting proteins (eg prothrombin), calcium antagonists (eg nimodipine), antihypertensives, platelets, plasma or other (specified).

prescribing practices for the use of certain drug combinations in the treatment of ischemic and hemorrhagic stroke used.

The proportion of hemorrhagic stroke patients treated surgically with aneurysm clipping, the endovascular treatment of aneurysms, surgical arteriovenous malformation (AVM), remove steriotactic radiosurgery, endovascular treatment of AVMs, the removal of the hematoma ventriculocisternostomie, carotid endarterectomy, craniotomy, and others indicated ().

From the perspective of the physician. current limitations in the diagnosis and treatment of diseases

For more information about the report, please visit:
or send us your request at: info@visionshopsters.com
———– ——– ———————— —